T&K: Registration of Pilocarpine Hydrochloride Eye Drops Accepted
T&K announced that its wholly-owned subsidiary Huabo Kaisheng has received the "Acceptance Notice" for the application for the registration and marketing authorization of the domestic production of Pilocarpine Hydrochloride Eye Drops issued by the National Medical Products Administration. This drug is classified as a chemical drug of category 3, with a specification of 1.25%, and the applicant is Huabo Kaisheng. Pilocarpine Hydrochloride Eye Drops can treat presbyopia in adults, and the original drug was developed by Allergan and has not yet been launched in the domestic market. Huabo Kaisheng is the first company in China to apply for and have accepted the generic drug listing application for this product
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments